Publication | Closed Access

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2Hematological MalignancyMedicineInhibitor ZiftomenibMixed-phenotype Acute LeukemiaImmunologyHematologyMyeloid NeoplasiaFirst-in-human StudyAdult T-cell Leukemia-lymphomaOncologyRadiation OncologyCancer ResearchHealth Sciences